JOM KITA KE POLITEKNIK

Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms (Record no. 1621)

MARC details
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Bertrums, Eline J.M.
Relator term author
9 (RLIN) 1254
245 00 - TITLE STATEMENT
Title Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. American Association for Cancer Research,
Date of publication, distribution, etc. 2022-08-05.
500 ## - GENERAL NOTE
General note /pmc/articles/PMC7613255/
500 ## - GENERAL NOTE
General note /pubmed/35678530
520 ## - SUMMARY, ETC.
Summary, etc. Childhood cancer survivors are confronted with various chronic health conditions like therapy-related malignancies. However, it is unclear how exposure to chemotherapy contributes to the mutation burden and clonal composition of healthy tissues early in life. Here, we studied mutation accumulation in hematopoietic stem and progenitor cells (HSPC) before and after cancer treatment of 24 children. Of these children, 19 developed therapy-related myeloid neoplasms (t-MN). Posttreatment HSPCs had an average mutation burden increase comparable to what treatment-naïve cells accumulate during 16 years of life, with excesses up to 80 years. In most children, these additional mutations were induced by clock-like processes, which are also active during healthy aging. Other patients harbored mutations that could be directly attributed to treatments like platinum-based drugs and thiopurines. Using phylogenetic inference, we demonstrate that most t-MN in children originate after the start of treatment and that leukemic clones become dominant during or directly after chemotherapy exposure. SIGNIFICANCE: Our study shows that chemotherapy increases the mutation burden of normal blood cells in cancer survivors. Only few drugs damage the DNA directly, whereas in most patients, chemotherapy-induced mutations are caused by processes similar to those present during normal aging. This article is highlighted in the In This Issue feature, p. 1825
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction ©2022 The Authors; Published by the American Association for Cancer Research
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
546 ## - LANGUAGE NOTE
Language note en
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element Research Briefs
9 (RLIN) 1267
655 7# - INDEX TERM--GENRE/FORM
Genre/form data or focus term Text
Source of term local
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Rosendahl Huber, Axel K.M.
Relator term author
9 (RLIN) 1255
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name de Kanter, Jurrian K.
Relator term author
9 (RLIN) 1256
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Brandsma, Arianne M.
Relator term author
9 (RLIN) 1257
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name van Leeuwen, Anaïs J.C.N.
Relator term author
9 (RLIN) 1258
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Verheul, Mark
Relator term author
9 (RLIN) 1259
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name van den Heuvel-Eibrink, Marry M.
Relator term author
9 (RLIN) 1260
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Oka, Rurika
Relator term author
9 (RLIN) 1261
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name van Roosmalen, Markus J.
Relator term author
9 (RLIN) 1262
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name de Groot-Kruseman, Hester A.
Relator term author
9 (RLIN) 1263
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Zwaan, C. Michel
Relator term author
9 (RLIN) 1264
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Goemans, Bianca F.
Relator term author
9 (RLIN) 1265
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name van Boxtel, Ruben
Relator term author
9 (RLIN) 1266
786 0# - DATA SOURCE ENTRY
Note Cancer Discov
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1158/2159-8290.CD-22-0120">http://dx.doi.org/10.1158/2159-8290.CD-22-0120</a>
Public note Connect to this object online.

No items available.